bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Fan, Yun;Liu, Yang;Wang, Liuchun;Cai, Yiran;Cao, Wen;...

通讯作者：

Huang, DZ;Pan, XJ

作者机构：

[Fan, Yun] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Med Thorac Oncol, Canc Hosp, Beijing, Peoples R China.

[Liu, Yang] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Pathol, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China.

[Huang, Dingzhi; Wang, Liuchun] Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjin Canc Inst &, Tianjin, Peoples R China.

[Zhang, Zhou; Han, Yusheng; Li, Bing; Chuai, Shannon; Cai, Yiran; Cai, Shangli; Sun, Wenjie; Zou, Xiao] Burning Rock Biotech, Guangzhou, Peoples R China.

[Cao, Wen] Hunan Univ Chinese Med, Dept Oncol & Hematol, Hosp 2, Changsha, Peoples R China.

通讯机构：

[Huang, DZ ] T

[Pan, XJ ] F

Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Thorac Oncol, Huanhuxi Rd, Tianjin 300060, Peoples R China.

Fujian Prov Hosp, Dept Chest Surg, Fuzhou 350001, Fujian, Peoples R China.

语种：

英文

关键词：

Intratumor heterogeneity;Immunotherapy;Immune checkpoint blockade;Predictive biomarker;Blood biopsy;NSCLC

期刊：

eBioMedicine

ISSN：

2352-3964

年：

2023

卷：

页码：

104564

DOI：

10.1016/j.ebiom.2023.104564

基金类别：

National Natural Science Foundation of China [81972718, 81572321]; Natural Scientific Foundation of Zhejiang Province, China [LY19H160007]; Science and Technology Program for Health and Medicine in Zhejiang Province, China [2021KY541]; Scientific Research Project, Science and Technology Department of Sichuan Province [21YYJC1616]; Sichuan Medical Association [S20002]; Wu Jieping Medical Foundation [320.6750]; Entrepreneurial Leading Talent of Guangzhou Huangpu District and Guangzhou Development District [2022-L023]

机构署名：

本校为其他机构

院系归属：

第二中医临床医学院

摘要：

Background Intratumor heterogeneity (ITH) has been associated with poor prognosis in advanced non-small cell cancer (NSCLC) patients receiving immune checkpoint blockade (ICB) therapies. However, there is currently no evidence supporting an ITH metric as a predictor of clinical benefit from ICB. The unique advantages of blood make it a promising material for ITH estimation and relevant applications. This study aims to develop and validate a blood-based ITH index for predicting ICB response.Methods NSCLC patients from the OAK and POPLAR clinical trials were used as the training cohorts for algo...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问